KPV
Cell and mouse studies only; no human data.
The last three amino acids of a natural anti-inflammatory hormone. It calms inflammation in cells and in mice with colitis. has found no record of it being given to people in a study. Also called Lys-Pro-Val and Alpha-MSH fragment 11-13.
What the evidence shows
Side effects and risks
Who should avoid it: Treat it as untested.
How it works
- Where it acts
- Thought to enter gut-lining and immune cells and dampen inflammatory signalling.
- What it changes
- In mice with colitis, less gut inflammation.
- What people notice
- No human data.
How it has been given in studies
No human dose exists.
Getting it in the United States
The legal route for KPV
Not FDA-approved. FDA advisers have reviewed, or are due to review, whether pharmacies may compound it. Until FDA acts, there is no lawful route. Vials sold for research use are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Online research-chemical and supplement sellers
Sold online in oral, topical and injectable forms, often as research chemicals or mislabelled supplements with no quality assurance. Compounding is not yet authorised.
Source: BSCG, 2026-07
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Calmer gut, usually from capsules
Reported problems
- Nothing noticeable
Based on very few reports.
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Voted 8-6 with one abstention to recommend KPV for pharmacy compounding for wounds and inflammatory conditions, against FDA staff advice.
Source: RAPS, 2026-07
FDA Pharmacy Compounding Advisory CommitteeSourceRecommends
Money: Several new members reported to have peptide ties
States it has found no human exposure data for KPV by any route and cannot tell whether it would cause harm.
Source: FDA, 2026-04
US Food and Drug AdministrationSourceWarns against
Voted no on KPV and described the peptide as a black box to him.
Josh MailmanWebsiteWarns against
Photo source: netrf.org
Says no published randomized human trial shows benefit, rodent colitis results do not support use in bowel disease, and athletes risk a violation under the non-approved substances rule.
Source: BSCG, 2026-07
Banned Substances Control GroupSourceWarns against
Said influencers and politics, not good science, drive peptide demand. Called a US advisory vote to ease compounding limits frustrating and hoped Health Canada would follow the science.
Source: CTV News via CP24, 2026-07
Timothy CaulfieldWikipediaWarns against
Told the public not to inject peptides bought online. Said unauthorized products are illegal, unproven and may cause organ damage, clots or tumour growth. A research-use-only label does not make them legal.
Source: Health Canada advisory, 2026-04
Health CanadaSourceWarns against
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
5 Things to Know About the FDA's Peptide Reversal
Habiba Atta, writer
Describes the July 2026 FDA advisory panel vote to back KPV for compounding, against the unanimous advice of agency scientists, plus gray-market contamination warnings.
Shows why KPV's legal status is contested.
When options run out
Uses people turn to when standard treatment has failed.
Inflammatory bowel disease
- Who
- People with Crohn's disease or ulcerative colitis seeking an add-on after standard drugs.
- Evidence
- Rodent studies only. KPV reduced colitis severity in two models. No human trial and no human exposure data known to FDA.
- Route
- None. Panel backed compounding in 2026-07 but rulemaking is pending.
Source: BSCG, 2026-07
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does KPV work for gut inflammation?
Only in cells and in mice with colitis, where it reduced gut inflammation. FDA has found no record of it being given to people in a study.
Do oral KPV capsules work?
Users report a calmer gut, usually from capsules, but the reports are very few and there is no human data to check them against.
Is KPV safe?
There are no human safety data, and FDA says it lacks the information to judge.
Is KPV legal in the US?
FDA advisers voted 8 to 6 in July 2026 to back compounding, but FDA staff opposed it and FDA had not acted by late September 2026.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- FDA: bulk substances that may present significant safety risks
- McDermott: July 2026 advisory committee votes
Structure: PubChem